Drug reference
ciraparantag
Synthetic small molecule · Antidote
Synthetic small moleculeAntidote
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Ciraparantag is a synthetic, small cationic molecule that is reported to bind dabigatran, rivaroxaban, apixaban, and edoxaban, as well as heparin and LMWH.
Indications
reversal of dabigatran, rivaroxaban, apixaban, edoxaban, heparin, and LMWH (currently in phase III clinical trials)
Related guidelines
Diabetic foot — clinical management
MOHFW · Endocrinology · 2021
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Trauma in elderly and frail patients
WSES · Surgery · 2023
Ask House about ciraparantag
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team